ZEP 3

Drug Profile

ZEP 3

Alternative Names: ZEP-3

Latest Information Update: 09 Nov 2015

Price : $50

At a glance

  • Originator SIS Shulov Innovative Science
  • Class Analgesics; Antivirals; Peptides; Skin disorder therapies
  • Mechanism of Action Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Herpes labialis
  • Phase I Herpesvirus infections

Most Recent Events

  • 01 Sep 2015 Phase-II clinical trials in Herpes labialis in Israel (Topical, ointment) (NCT02483182)
  • 30 Jun 2015 SIS Shulov Innovate Science plans a phase II trial for Herpes labialis in Israel (NCT02483182)
  • 01 Feb 2014 SIS Shulov Innovate Science completes a phase I trial in healthy volunteers in Israel (NCT01863160)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top